GRANDE, VERA
 Distribuzione geografica
Continente #
EU - Europa 2.995
NA - Nord America 2.203
AS - Asia 1.746
Continente sconosciuto - Info sul continente non disponibili 326
SA - Sud America 142
AF - Africa 56
OC - Oceania 6
Totale 7.474
Nazione #
US - Stati Uniti d'America 2.154
GB - Regno Unito 1.490
CN - Cina 632
SG - Singapore 475
IT - Italia 328
DE - Germania 290
SE - Svezia 207
RU - Federazione Russa 173
FR - Francia 165
HK - Hong Kong 152
UA - Ucraina 121
BD - Bangladesh 114
IN - India 88
BR - Brasile 83
VN - Vietnam 72
NL - Olanda 68
KR - Corea 66
FI - Finlandia 55
EU - Europa 53
TR - Turchia 52
CI - Costa d'Avorio 44
IE - Irlanda 37
JP - Giappone 33
CA - Canada 32
CO - Colombia 30
ID - Indonesia 19
BE - Belgio 15
EC - Ecuador 10
GR - Grecia 10
DK - Danimarca 8
TW - Taiwan 6
AR - Argentina 5
AU - Australia 5
ES - Italia 5
PL - Polonia 5
SA - Arabia Saudita 5
UZ - Uzbekistan 5
ZA - Sudafrica 5
CL - Cile 4
IQ - Iraq 4
MX - Messico 4
VE - Venezuela 4
CZ - Repubblica Ceca 3
MY - Malesia 3
PE - Perù 3
PH - Filippine 3
PK - Pakistan 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BY - Bielorussia 2
CH - Svizzera 2
CR - Costa Rica 2
GT - Guatemala 2
LU - Lussemburgo 2
MA - Marocco 2
NG - Nigeria 2
NP - Nepal 2
PA - Panama 2
PT - Portogallo 2
RO - Romania 2
AL - Albania 1
AT - Austria 1
BF - Burkina Faso 1
BG - Bulgaria 1
BH - Bahrain 1
DO - Repubblica Dominicana 1
EG - Egitto 1
GH - Ghana 1
HN - Honduras 1
IL - Israele 1
JM - Giamaica 1
KH - Cambogia 1
KW - Kuwait 1
KZ - Kazakistan 1
LB - Libano 1
LC - Santa Lucia 1
NC - Nuova Caledonia 1
NO - Norvegia 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
VI - Stati Uniti Isole Vergini 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 7.202
Città #
Southend 1.382
Singapore 256
Ashburn 215
Milan 150
Hong Kong 145
Chandler 129
Beijing 128
Santa Clara 126
San Jose 119
Seattle 111
Jacksonville 96
Dallas 85
Ann Arbor 70
Wilmington 70
Council Bluffs 67
Berlin 64
Princeton 60
Los Angeles 56
Woodbridge 56
Dearborn 55
Fairfield 54
Abidjan 44
Bengaluru 40
Mountain View 39
Nanjing 39
Dublin 37
Redmond 37
Jinan 35
Serra 33
Houston 31
Moscow 29
Bogotá 28
Helsinki 28
Boardman 26
Andover 25
Ho Chi Minh City 25
Sakarya 25
Shanghai 25
Lauterbourg 24
New York 24
Shenyang 24
Buffalo 23
Tianjin 22
Guangzhou 21
Frankfurt am Main 20
Hefei 20
Medford 20
Phoenix 20
Scranton 20
Cambridge 18
Seoul 18
Somerville 18
Des Moines 17
Ningbo 17
Hangzhou 16
Toronto 16
Brussels 15
Hanoi 15
The Dalles 15
Tokyo 15
Nanchang 14
Changsha 12
Columbus 12
Bühl 11
Jakarta 11
Kiez 11
Saint Petersburg 11
Athens 10
Hebei 10
Hillsboro 10
Redwood City 9
Auburn Hills 8
Brooklyn 8
Chicago 8
Cincinnati 8
San Diego 8
Shenzhen 8
Verona 8
Cangzhou 7
Falls Church 7
Lansing 7
Elk Grove Village 6
Fuzhou 6
Kunming 6
Nürnberg 6
Quanzhou 6
Turin 6
Bergamo 5
Da Nang 5
Denver 5
Eitensheim 5
Madison 5
São Paulo 5
Atlanta 4
Baghdad 4
Bitonto 4
Bloomsbury 4
Charlotte 4
Detroit 4
Eygelshoven 4
Totale 4.750
Nome #
Anti-EGFR Antibody Efficiently and Specifically Inhibits Human TSC2-/- Smooth Muscle Cell Proliferation. Possible Treatment Options for TSC and LAM 490
G protein-mediated signal transduction is affected in primary biliary cirrhosis 403
Isolation and growth of smooth muscle-like cells derived from tuberous sclerosis complex-2 human renal angiomyolipoma : epidermal growth factor is the required growth factor 377
Expression of the anti-apoptotic protein survivin amd altered function of IGF-1 pathway in TSC2 brain tubers 305
Survivin expression in tuberous sclerosis complex cells 298
Characterization of LAM/TSC cells isolated from patient chylous 297
TSC2 epigenetic defect in primary LAM cells. Evidence of an anchorage-independent survival 292
Proliferation and invasiveness of human smooth muscle TSC2-/- : Effect of anti-EGFR and rapamycin 291
A mouse LAM model by endonasal administration of human TSC2 deficient smooth muscle cells 287
Exploring the role of MKK7 in excitotoxicity and cerebral ischemia : a novel pharmacological strategy against brain injury 286
Development of a LAM model by using human TSC2-/- cells derived from a renal angiomyolipoma : A pharmacological evaluation 285
Pathogenesis and pharmacological evaluation of human TSC2 smooth muscle cells. Possible treatment options for TSC and lymphangioleiomyomatosis 276
Farmacologia 264
Human smooth muscle TSC2-/- cells cause lymphangiogenesis-like lung destruction in nude mice. Pharmacological repair 264
Un modello di linfangioleiomiomatosi con la somministrazione di cellule muscolari lisce umane TSC2-/- 264
Phenotype reversion of human TSC2-/- smooth muscle cells 256
PATHOGENESIS AND PHARMACOLOGY OF ISOLATED HUMAN TSC2 SMOOTH MUSCLE CELLS. NOVEL THERAPEUTIC PERSPECTIVES 252
Development of a LAM model by using human TSC2 deficient smooth muscle cells derived from a renal angiomylipoma 244
Role of HMG-CoA reductase inhibitors in controlling TSC2-/- ASM cell growth and proliferation 241
Molecular characterization of growth and survival of human TSC2 gene-deficient smooth muscle-like cells 239
An epigenetic event may underlies the TSC features in TSC2 ASM cells 238
Reversion of the phenotype of human TSC2-/- smooth muscle cells 235
Promoter methylation of TSC2 gene is important for pathogenesis of TSC and LAM lesions 235
Anti-EGFR antibody efficiently and specifically inhibits human TSC2-/- smooth muscle cell proliferation. Possible treatment options for TSC and LAM 232
Isolation and growth characterization of two types of human TSC2 gene-deficient cells 225
Pharmacological and biochemical characterization of isolated and in vitro grown human TSC2 gene-deficient smooth muscle-like cells 219
Pharmacological reversion of the phenotype of human TSC2-/- smooth muscle cells 179
Totale 7.474
Categoria #
all - tutte 16.734
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.734


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022399 0 28 29 19 30 13 43 11 75 44 16 91
2022/2023489 55 57 35 68 66 75 4 28 70 4 17 10
2023/2024319 12 19 18 26 80 42 3 29 12 14 26 38
2024/2025717 36 62 18 88 102 15 13 74 25 74 62 148
2025/20261.643 181 93 205 124 138 108 207 68 128 108 181 102
2026/2027175 86 89 0 0 0 0 0 0 0 0 0 0
Totale 7.474